DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.

Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

The Journal of Pharmaceutical Innovation, published by SPRINGER, serves as a vital resource in the fields of Pharmaceutical Science and Drug Discovery. With an ISSN of 1872-5120 and an E-ISSN of 1939-8042, this journal has been disseminating significant research findings since its inception in 2006. It is recognized for its rigorous peer-review process, maintaining a respectable ranking of Q2 in Pharmaceutical Science and Q3 in Drug Discovery as of 2023. Researchers and practitioners benefit from the journal's diverse scope, which encompasses innovative methodologies and advancements in pharmaceuticals, thereby fostering knowledge and collaboration within the scientific community. Although it does not offer Open Access options, the journal is accessible through institutional subscriptions and libraries, ensuring that critical insights in drug development and pharmacology reach a broad audience. The geographical presence of the journal in the United States underscores its influence in shaping the pharmaceutical landscape on a global scale.

Pharmaceutical Sciences, an esteemed journal published by Tabriz University of Medical Sciences, Faculty of Pharmacy, serves as a crucial platform for the dissemination of pioneering research in the fields of pharmaceutical science, pharmacology, and toxicology. With an impact factor reflective of its substantial contribution to the scientific community, this open access journal has been accessible since 2012, ensuring that researchers, professionals, and students worldwide can engage with its rich content. Located in Iran, it has continually evolved, covering research from 2009 to 2024, and boasts impressive rankings in multiple Scopus categories, including Q3 in Pharmaceutical Science and Q2 in Pharmacology, Toxicology and Pharmaceutics. By bridging gaps between scientific inquiry and practical applications, Pharmaceutical Sciences is dedicated to advancing pharmaceutical knowledge and promoting innovative practices that address significant health challenges.

PHARMACEUTICAL RESEARCH, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the ever-evolving field of pharmaceutical sciences. With an ISSN of 0724-8741 and an E-ISSN of 1573-904X, this journal has established itself as a critical hub for disseminating innovative research from 1984 to 2024. The journal holds impressive rankings in prominent categories, including Q2 in Biotechnology and Q2 in Pharmaceutical Science, reflecting its robust impact on the global scientific community. The journal aims to provide researchers, professionals, and students with high-quality articles that contribute significantly to the advancement of drug development and medicinal applications. Although it does not currently offer Open Access options, its rigorous peer-review process ensures that only the highest caliber research is published, making it a valuable resource for those seeking to stay at the forefront of pharmaceutical innovation.

XENOBIOTICA is a premier journal in the field of pharmacology and toxicology, published by Taylor & Francis Ltd. With an ISSN of 0049-8254 and E-ISSN 1366-5928, this journal has been at the forefront of research since 1971, providing critical insights and advancements up until 2024. It is recognized for its rigorous peer-reviewed content, occupying a third quartile ranking across various categories including Biochemistry, Health, Toxicology, and Pharmacology as of 2023. The journal serves as a pivotal platform for disseminating innovative findings that address the impact of xenobiotics on health and the environment, making it an essential resource for researchers, professionals, and students engaged in these multidisciplinary fields. While it does not currently offer open access, it is widely respected for its contribution to science, evidenced by its Scopus rankings across different areas of study. The journal encourages submissions that push the boundaries of knowledge and transform our understanding of the effects of chemical substances on living organisms.

Cancer Chemotherapy and Pharmacology, published by Springer, is a leading peer-reviewed journal that plays a crucial role in the field of cancer research and drug therapy. With an ISSN of 0344-5704 and an E-ISSN of 1432-0843, this journal has been a cornerstone of oncology and pharmacology research since its inception in 1978, with continued relevance through to 2024. The journal holds a commendable Q2 ranking in categories such as Cancer Research, Oncology, and Pharmacology (medical), while achieving an elite Q1 status in Toxicology, reflecting its high-impact contributions to the scientific community. Researchers and professionals benefit from access to cutting-edge studies, insightful reviews, and innovative methodologies, making it a vital resource for anyone working at the intersection of pharmacology and oncology. Although not an open-access journal, Cancer Chemotherapy and Pharmacology remains highly accessible through institutional subscriptions, ensuring it reaches a broad audience dedicated to advancing cancer treatment and patient care.

The International Journal of Pharmaceutics, a prestigious publication from ELSEVIER, stands at the forefront of the pharmaceutical science field, exemplified by its impressive ranking of #15 out of 183 in Pharmacology, Toxicology, and Pharmaceutics, placing it in the 92nd percentile. Established in 1978, this journal has continuously provided a platform for researchers, professionals, and students to share groundbreaking discoveries and innovations in drug formulation, delivery systems, and pharmacokinetics. With a Q1 ranking in the 2023 category of Pharmaceutical Science, it underscores its significance in disseminating high-quality research that shapes clinical practices and enhances therapeutic outcomes. While the journal does not currently offer open access options, it remains accessible to subscribers through its publication based in Amsterdam, Netherlands, ensuring a broad reach within the scientific community. As it converges towards a vibrant future, the International Journal of Pharmaceutics continues to be an essential resource for anyone dedicated to advancing the field of pharmacy and drug development.

PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY is a premier journal published by Taylor & Francis Ltd that focuses on the latest advancements and innovations in the field of pharmaceutical science. Established in 1996, this journal has evolved to encompass a wide array of interdisciplinary studies relevant to drug development, formulation technology, and delivery systems, serving as a platform for researchers and professionals to share groundbreaking findings. With an impressive impact factor and ranked in both Q2 in Pharmaceutical Science and Q3 in Medicine (miscellaneous), it positions itself among the top-tier journals in pharmacology and toxicology. The journal's insights are critical for scholars and practitioners aiming to enhance therapeutic efficacy and safety. Access options for the content remain traditional, thus supporting a comprehensive approach to scientific literature. Throughout its converged years up to 2024, PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY continues to play a vital role in shaping pharmaceutical education and practice.